Introduction It is increasingly clear that RSV infections in older adults significantly impact the UKs already strained public health system. However, the true burden remains underestimated (Korsten K, Eur Respir J, 2021, 57, 2,002,688; Sharp A, Influenza Other Respir Viruses, 2022, 16, 125–131). We conducted a TLR to scrutinise the available data and reveal evidence gaps. Methods A TLR search was conducted in OVID Medline, Embase, and ECON Lit to identify existing literature from Jan 2011-Aug 2023 and grey literature. Eligibility criteria were defined based on population (intervention/comparator (no limit), outcomes (clinical, epidemiological, economic and QoL) and limited to UK-only results. Results Despite the broad criteria, only 14 out of 1013 studies were included. Nine studies reported on epidemiological outcomes, one on epidemiology and costs, and four on model outcomes. Due to the small number of studies and the heterogeneity in study design and outcomes, it was not possible to draw reliable conclusions on incidence, prevalence, and mortality. One model paper showed that a hypothetical RSV vaccine could be cost effective in the UK, depending on incidence, vaccine effectiveness and cost. All identified studies emphasise the challenges in estimating the true burden due to limitations in testing and a lack of standardised disease definition in older adults. There is a lack of evidence for risk groups, particularly clinical and economic consequences for RSV patients at a higher risk of infection and severe sequelae. Conclusion Only a limited number of studies meeting the criteria focused on RSV infection in older adults were found, with nearly no data on risk groups and related cost. It is imperative that surveillance and testing are improved to understand the true burden. This will serve as a basis for evaluating cost-effectiveness and decisions on the most effective measures to lower the burden, including vaccination programmes.

中文翻译：

---

2352 英国 60+ 成人呼吸道合胞病毒 （RSV） 的疾病负担：靶向文献综述 （TLR）


引言 越来越明显的是，老年人的 RSV 感染对英国本已紧张的公共卫生系统产生了重大影响。然而，真正的负担仍然被低估了（Korsten K， Eur Respir J， 2021， 57， 2,002,688;夏普 A，流感其他呼吸病毒，2022,16,125-131）。我们进行了 TLR 以仔细检查现有数据并揭示证据差距。方法 在 OVID Medline 、 Embase 和 ECON Lit 中进行 TLR 检索，以确定 2011 年 1 月至 2023 年 8 月的现有文献和灰色文献。资格标准是根据人群（干预/对照（无限制）、结果（临床、流行病学、经济和 QoL）定义的，仅限于英国的结果。结果 尽管标准很宽泛，但 1013 项研究中仅纳入了 14 项。9 项研究报告了流行病学结局，1 项研究报告了流行病学和成本，4 项研究报告了模型结局。由于研究数量少以及研究设计和结局的异质性，无法得出关于发病率、患病率和死亡率的可靠结论。一篇模型论文表明，假设的 RSV 疫苗在英国可能具有成本效益，具体取决于发病率、疫苗有效性和成本。所有已确定的研究都强调了由于检测的局限性和缺乏老年人标准化疾病定义而在估计真实负担方面的挑战。缺乏关于风险群体的证据，特别是对感染和严重后遗症风险较高的 RSV 患者的临床和经济后果。结论 仅发现有限数量的符合标准的研究侧重于老年人 RSV 感染，几乎没有关于风险人群和相关成本的数据。 当务之急是改进监测和检测以了解真正的负担。这将作为评估成本效益和决定减轻负担的最有效措施（包括疫苗接种计划）的基础。